DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition
STRATEC completes acquisition of Diatron
Birkenfeld, April 1, 2016
STRATEC Biomedical AG, Birkenfeld, Deutschland (Frankfurt: SBS; Prime Standard, TecDAX) today announces the successful completion of the acquisition of Diatron MI PLC (Diatron). On March 23, 2016, STRATEC announced that it entered into an agreement with the global private equity firm The Riverside Company governing the full acquisition of Diatron, its US affiliate company and the superordinate holding structure.
With the acquisition of Diatron, STRATEC is extending its range of products and its customer base in the hematology segment. Diatron's OEM portfolio chiefly comprises analyzer systems, system components, consumables and tests in the lower throughput segment for hematology applications.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX|
|End of News||DGAP News Service|